Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab combinations in PD-1/PD-L1 refractory NSCLC
NCT03334617Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2017
- Primary completion
- Sep 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 8
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Dec 2017; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03334617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03334617.